How has been the historical performance of Gland Pharma?

Revenue and Profitability Trends

Gland Pharma’s net sales have shown a robust upward trend from ₹2,633.24 crores in March 2020 to ₹5,616.50 crores in March 2025, effectively more than doubling over this period. The company experienced a notable surge between March 2022 and March 2024, with sales peaking at ₹5,664.72 crores in March 2024 before a slight dip in the latest fiscal year. Despite this minor decline, the overall revenue trajectory remains positive, reflecting strong market demand and operational scale.

Operating profit margins, excluding other income, have moderated from a high of 37.61% in March 2021 to 22.59% in March 2025. This contraction suggests rising costs or pricing pressures, although the company maintained a healthy operating profit of ₹1,268.92 crores in the latest year. Gross profit margins have similarly declined from over 41% in earlier years to 25.65% most recently, indicating increased input costs or competitive dynamics impacting profitability.

Profit after tax (PAT) has followed a fluctuating pattern, peaking at ₹1,211.66 crores in March 2022 before settling at ₹698.53 crores in March 2025. Correspondingly, the PAT margin decreased from nearly 29.35% in March 2020 to 12.44% in the latest fiscal year. Earnings per share (EPS) mirrored this trend, reaching a high of 73.75 in March 2022 and moderating to 42.39 by March 2025. These figures underscore the company’s capacity to generate substantial profits, albeit with some margin pressure in recent years.

Cost Structure and Expenditure Analysis

The company’s total expenditure excluding depreciation rose significantly from ₹1,677.77 crores in March 2020 to ₹4,347.58 crores in March 2025, reflecting the scale of operations and inflationary pressures. Raw material costs have increased steadily, reaching ₹1,972.48 crores in the latest year, while employee costs surged from ₹277.66 crores to ₹1,401.56 crores over the same period, indicating investment in human capital and expansion.

Power costs and other expenses have also escalated, with power costs rising to ₹199.15 crores and other expenses to ₹656.48 crores by March 2025. Notably, the company reported negligible selling and distribution expenses, suggesting a possible focus on direct sales or efficient distribution channels. Despite rising costs, Gland Pharma has managed to sustain a positive operating profit, supported by other income which increased to ₹213.61 crores in the latest fiscal year.

Balance Sheet and Asset Growth

Gland Pharma’s total assets have expanded from ₹4,086.04 crores in March 2020 to ₹11,172.85 crores in March 2025, reflecting substantial capital investment and business growth. The net block of fixed assets increased markedly to ₹4,104.44 crores, supported by a gross block of ₹5,545.58 crores, indicating ongoing capacity enhancement and infrastructure development.

Shareholders’ funds have grown impressively from ₹3,646.24 crores to ₹9,150.74 crores, bolstered by reserves rising to over ₹9,134 crores. The company’s book value per share has nearly doubled from ₹235.32 to ₹555.40, signalling enhanced net worth and shareholder value creation. Total debt remains modest at ₹269.21 crores, suggesting a conservative leverage approach and strong financial health.

Cash Flow and Liquidity Position

Cash flow from operating activities has shown a positive trend, increasing from ₹700 crores in March 2020 to ₹914 crores in March 2025, despite some volatility in intervening years. Investing activities reflect significant capital expenditure, with a notable outflow of ₹1,717 crores in the latest year, consistent with asset growth. Financing activities have seen net outflows recently, indicating debt repayments or shareholder returns.

The company’s cash and bank balances surged to ₹2,556.21 crores by March 2025, up from ₹1,325.19 crores in March 2020, underscoring strong liquidity and prudent cash management. Net cash inflow of ₹2,199 crores in the latest fiscal year contrasts with a substantial outflow in the previous year, highlighting improved cash generation and operational efficiency.

Summary and Outlook

Over the past six years, Gland Pharma has exhibited strong revenue growth and expanded its asset base significantly, while maintaining profitability despite margin pressures. The company’s conservative debt levels and robust cash reserves provide a solid foundation for future expansion. Although operating and PAT margins have contracted from their peaks, the firm continues to generate healthy profits and invest in capacity enhancement.

Investors should note the company’s ability to sustain growth amid rising costs and competitive challenges, supported by a strong balance sheet and cash flow position. The historical performance underscores Gland Pharma’s resilience and potential for continued value creation in the pharmaceutical sector.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →